Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Edwards Lifesciences Corporation (EWL) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Edwards Lifesciences Corporation €72.18, price €76.34, upside -5.5%, quality 67 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
EL
Broad data
Sep 29, 2026
Edwards Lifesciences Corporation
EWL · XETRANeutralQuality growthThe stock looks roughly fairly valued with average quality.
·Fair value €72.18 · Fairly valued (−5.5%)
✓Quality 67/100
!Mixed Growth (revenue 3y +10.8 %/yr)
✓Solidly profitable · 17.4% net margin (TTM)
✓Low debt · generates free cash flow
✓Wide moat 70/100
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Sep 29, 2026.
How to read this chart
10‑month range €63.38 – €83.04 · fair‑value band €54.14 – €90.22 · the €76.34 price screens above the €72.18 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Sep 29, 2026.
Company profile
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
Show more
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Stock analysis
Edwards Lifesciences Corporation (EWL) currently trades at €76.34, while our model-based Fair Value estimate is €72.18, so the stock looks roughly fairly valued today (gap 5.8%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €43.58 per share, and 0 of the 24 models we run sit above the €76.34 price.
Bear case: the Asset-Based group reads lowest at €10.69, and 24 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: €54.14 (bear) to €90.22 (bull), the price of €76.34 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Edwards Lifesciences Corporation reported revenue of $6.1B in FY2025 versus $5.2B in FY2021, a compound +3.8%/yr. Reported net income was $1.1B in FY2025, compounding −8.1%/yr from FY2021.
Key figures
Market cap €44.3B · P/E ratio 46.8 · P/S ratio 8.29 · EPS (TTM) €1.63 · Net margin 17.7% · Return on equity 10.5% · Return on assets (EBIT) 15.3% · Operating margin 31.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −5%, EWL screens richer than that median.
Fair Value models
Bear €54.14
Fair Value €72.18
Bull €90.22
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€1.23 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
€28.80
€45.87
€73.67
76
Growth DCF
€28.94
€45.38
€71.93
74
Owner Earnings
€22.00
€34.45
€54.74
72
All 24 models by family
DCF Models
FCF DCF
€28.80
€45.87
€73.67
76
Owner Earnings
€22.00
€34.45
€54.74
72
5Y Revenue Exit
€24.73
€38.25
€55.91
69
5Y EBITDA Exit
€29.54
€47.69
€69.60
71
5Y P/E Exit
€28.50
€45.66
€64.41
67
10Y Revenue Exit
€25.29
€38.29
€56.76
64
10Y EBITDA Exit
€29.05
€45.03
€67.70
65
10Y P/E Exit
€28.38
€43.58
€63.56
61
Earnings-Based
Graham-Dodd
€11.26
€43.53
€59.01
61
Lynch FV
€10.65
€15.22
€19.79
58
PEG = 1.0
€10.65
€15.22
€19.79
55
EPV
€22.60
€25.77
€28.54
71
Multiples
P/E Multiple
€27.33
€36.43
€45.54
63
P/S Multiple
€21.12
€28.15
€35.19
58
P/B Multiple
€21.12
€28.15
€35.19
55
EV/EBIT
€35.79
€46.52
€57.25
66
EV/EBITDA
€32.65
€42.33
€52.01
67
EV/Revenue
€23.27
€31.69
€40.12
54
Asset-Based
NCAV (Graham)
€7.97
€10.69
€15.95
54
Growth DCF
Growth DCF
€28.94
€45.38
€71.93
74
Rev-Margin DCF
€24.73
€38.15
€54.57
69
Economic Profit
Residual Income
€14.20
€15.87
€20.86
68
ROIC Compounder
€24.45
€31.21
€39.99
69
Growth Earnings
Growth-Adj P/E
€19.75
€28.21
€36.67
65
Notify me when EWL reaches fair value
Put EWL on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
67/100
Of which business quality 69 · Market factors (momentum, volatility) 54
Profitability
52
Margins and returns on capital today
Quality Growth
39
Are margins and returns improving?
Cashflow
82
Earnings quality: real cash, not paper profit
Fin. Strength
94
Balance sheet, leverage, solvency risk
Investment
32
Disciplined investing over empire-building
Low Volatility
72
Calm price path (market factor)
Momentum
44
Price trend over the last 3–12 months (market factor)
52W Momentum
51
Distance to the 52-week high (market factor)
Net Issuance
96
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
88/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+11.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.8%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−5.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.2%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.30% → 27%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+17.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +14.5% a year for the price and +6.4% for the forecasts.
Forecast 2026 (sales)+11.2%
Forecast 2027 (sales)+9.8%
Projected 2028 (sales)+8.8%
Projected 2029 (sales)+7.9%
Projected 2030 (sales)+6.9%
Watch EWL, get fair value alerts →
Compare Edwards Lifesciences Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Context: sector, industry, market
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: German Stocks
- Valuation of the Germany market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $98.83 | $74.79 | −24% |
| Medtronic plc MDT | $87.09 | $65.61 | −25% |
| Stryker Corporation SYK | $278.77 | $306.65 | +10% |
| Boston Scientific Corporation BSX | $43.65 | $48.02 | +10% |
| Siemens Healthineers AG SHL | €37.86 | €35.19 | −7% |
| DexCom, Inc DXCM | $86.68 | $95.35 | +10% |
| GE HealthCare Technologies Inc GEHC | $66.63 | $70.37 | +6% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.86 | ¥169.25 | +10% |
| Koninklijke Philips N.V PHIA | €21.87 | €15.23 | −30% |
| STERIS plc STE | $208.93 | $229.82 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Edwards Lifesciences Corporation (EWL) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of €72.18 versus a price of €76.34, about −5% upside (fairly valued).
What is the fair value of EWL?
Our model-based fair value for Edwards Lifesciences Corporation is €72.18 (as of Sep 29, 2026), built from audited fundamentals. The current price: €76.34.
What is the quality score of EWL?
Edwards Lifesciences Corporation has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Edwards Lifesciences Corporation (EWL)?
Our model-based price target is the fair value of €72.18 (as of Sep 29, 2026) from 24 valuation models. Cautious scenario €54.14, optimistic scenario €90.22. It is a calculation from audited fundamentals, not an analyst target.
What is the Edwards Lifesciences Corporation stock forecast for 2026?
Our models put fair value at €72.18, about −5% upside versus a price of €76.34 (fairly valued). Cautious scenario €54.14, optimistic scenario €90.22. The calculation is refreshed regularly with new filings.
What is the revenue of Edwards Lifesciences Corporation (EWL)?
Edwards Lifesciences Corporation reported trailing-twelve-month revenue of about $6.3B (latest available figure, as of Sep 29, 2026).
What growth is priced into Edwards Lifesciences Corporation (EWL)?
For today's price to be fair in a discounted-cash-flow model, Edwards Lifesciences Corporation would have to grow free cash flow by +17.3 % per year for five years (discount rate 8.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +3.8 % per year. As of Sep 29, 2026.
What discount rate (WACC) does the fair value of EWL use?
Our models discount Edwards Lifesciences Corporation at 8.7 %: a base by market capitalisation (large), damped by beta 0.86, country premium for Germany. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Edwards Lifesciences Corporation that is +17.3 % per year a year over ten years, using the same discount rate (8.7 %) and the same formula as our fair value.
How much growth has Edwards Lifesciences Corporation (EWL) delivered so far?
Over the past 4 years revenue at Edwards Lifesciences Corporation grew +3.8 % a year. The price currently implies +17.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Edwards Lifesciences Corporation (EWL) growing?
The median revenue growth in the sector is +1.9 % a year. That is the yardstick for the growth priced into Edwards Lifesciences Corporation (+17.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Edwards Lifesciences Corporation (EWL)?
The free-cash-flow yield on the price is 2.68 %: that much free cash flow Edwards Lifesciences Corporation produces per unit of market value. When it exceeds the discount rate of our models (8.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Edwards Lifesciences Corporation (EWL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Edwards Lifesciences Corporation it is €72.18 per share (as of Sep 29, 2026), against a price of €76.34. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Edwards Lifesciences Corporation stock overvalued or undervalued in 2026?
As of Sep 29, 2026, EWL trades above its calculated fair value: price €76.34, fair value €72.18, a gap of about −5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EWL?
No. The price is what the market pays today (€76.34); the fair value is what the company's own numbers justify (€72.18). For Edwards Lifesciences Corporation the two are €4.16 per share apart. That gap is exactly why we show both numbers side by side.
How much is Edwards Lifesciences Corporation worth?
The market values Edwards Lifesciences Corporation at about €44.3B (market capitalisation, as of Sep 29, 2026). Per share that is €76.34; our models calculate a fair value of €72.18 per share.
What do the bullish and bearish scenarios say about EWL?
Our models span a range for Edwards Lifesciences Corporation: cautious scenario €54.14, base €72.18, optimistic €90.22 per share (as of Sep 29, 2026, price €76.34). The range comes from different growth and margin assumptions, not from analyst opinions.
Which stocks are comparable to Edwards Lifesciences Corporation?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Edwards Lifesciences Corporation stock attractive at the current price?
The data as of Sep 29, 2026: price €76.34, calculated fair value €72.18 (−5%), Quality Score 67/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EWL calculated?
We run Edwards Lifesciences Corporation through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €72.18, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Edwards Lifesciences Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Edwards Lifesciences Corporation (EWL)?
The closing price on Oct 2, 2026 was €76.34. Our model-based fair value is €72.18, about −5% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Edwards Lifesciences Corporation right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the upper half of our model range, so the margin of safety is thin. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Edwards Lifesciences Corporation
How large is the market capitalisation of Edwards Lifesciences Corporation (EWL)?
The market capitalisation of Edwards Lifesciences Corporation is €44.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Edwards Lifesciences Corporation (EWL)?
The price-to-earnings ratio of Edwards Lifesciences Corporation is 46.8. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Edwards Lifesciences Corporation (EWL)?
The price-to-sales ratio of Edwards Lifesciences Corporation is 8.29 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Edwards Lifesciences Corporation (EWL)?
Earnings per share at Edwards Lifesciences Corporation are €1.63 (price ÷ EPS = P/E 46.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Edwards Lifesciences Corporation (EWL)?
The net margin of Edwards Lifesciences Corporation is 17.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Edwards Lifesciences Corporation (EWL)?
The return on equity (ROE) of Edwards Lifesciences Corporation is 10.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Edwards Lifesciences Corporation (EWL)?
On an EBIT basis the return on assets of Edwards Lifesciences Corporation is 15.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Edwards Lifesciences Corporation (EWL)?
The operating margin of Edwards Lifesciences Corporation is 31.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Edwards Lifesciences Corporation (EWL)?
Revenue at Edwards Lifesciences Corporation is growing +16.7% versus a year earlier (3y avg +10.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Edwards Lifesciences Corporation (EWL)?
Earnings per share at Edwards Lifesciences Corporation are growing +8.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
Open the live analysis →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.